Mepolizumab Shows No Link Between Airway Dysfunction & Asthma Exacerbations in Kids
Children with exacerbation-prone asthma who received mepolizumab did not show a significant link between baseline airway dysfunction and exacerbation risk, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting. This finding contrasts with placebo recipients, where greater baseline airway resistance was associated with increased exacerbation rates. The research, led by Courtney Gaberino, MD, at the University of Wisconsin-Madison, suggests a potential protective effect of anti-IL5 therapy—mepolizumab—in children experiencing small airway dysfunction.
Airway Resistance and Asthma Exacerbations
The study focused on 271 children and adolescents aged 6 to 17 with asthma prone to exacerbations and a blood eosinophil count of at least 150 cells/μL. Participants received either mepolizumab (Nucala, GlaxoSmithKline) or a placebo for 52 weeks, continuing with standard asthma care throughout the trial. Researchers analyzed how baseline lung function measurements impacted exacerbation risk. Impulse oscillometry, a technique used to assess airway resistance, was a key component of the analysis. Previous research has identified inflammatory drivers of asthma exacerbations in children receiving mepolizumab.
Among those receiving the placebo, a significant correlation emerged between higher airway resistance at 5 Hz (beta = 2; P = .016), 5 Hz to 20 Hz (beta = 2.31; P = .068) and the area under the curve of reactance (beta = 0.26; P = .096) and an increased risk of exacerbations. However, this link was not observed in the mepolizumab group. “We found that greater baseline airway resistance…was associated with increased exacerbation rates during the trial for participants receiving placebo, but not mepolizumab,” explained Dr. Gaberino to Healio. Dr. Gaberino can be reached for further information.
Understanding Impulse Oscillometry
Impulse oscillometry measures lung function during normal breathing, offering a complementary assessment to spirometry, particularly in detecting small airway dysfunction. Even as not yet widely available in clinical practice, it provides valuable insights into airway resistance. The study also examined spirometry parameters. Lower baseline FEV1/FVC ratios were significantly linked to higher exacerbation frequencies in both the placebo group (beta = –3.02; P = .009) and the mepolizumab group (beta = –2.41; P = .04). Similarly, lower baseline FEV1 percent predicted was associated with greater exacerbation frequency, though this finding did not reach statistical significance in either group (placebo, beta = –0.009; mepolizumab, beta = –0.01).
Mepolizumab and IL-5 Inhibition
Mepolizumab is a monoclonal antibody that targets interleukin-5 (IL-5), a cytokine involved in the production and activation of eosinophils, a type of white blood cell implicated in asthma inflammation. By inhibiting IL-5, mepolizumab reduces eosinophil levels, potentially mitigating airway inflammation and improving asthma control. Research suggests that a six-month asthma control score on mepolizumab can predict remission in eosinophilic asthma.
Study Limitations and Future Directions
The study’s findings, while promising, are subject to certain limitations. The interaction between treatment group and impulse oscillometry parameters in predicting exacerbation risk did not reach statistical significance. This suggests that while mepolizumab may offer a protective effect in those with small airway dysfunction, the overall impact may not be substantial enough to be detected in this study population. Further research is needed to explore this relationship in more detail.
The researchers emphasize that impulse oscillometry is not currently a standard clinical tool, limiting its immediate applicability. However, as the technology becomes more accessible, it could play a greater role in identifying patients who might benefit from targeted therapies like mepolizumab. The study highlights the complex interplay between airway dysfunction, inflammation, and asthma exacerbations, and underscores the need for personalized approaches to asthma management.
Implications for Asthma Management
These findings contribute to a growing body of evidence supporting the employ of biologics, such as mepolizumab, in carefully selected asthma patients. While traditional asthma treatments focus on bronchodilation and reducing inflammation, biologics target specific inflammatory pathways, offering a more precise approach. The study suggests that assessing airway resistance, particularly in children with exacerbation-prone asthma, could help identify those most likely to respond to anti-IL5 therapy.
The American Academy of Allergy, Asthma & Immunology continues to refine its guidelines for asthma management based on emerging research. Ongoing clinical trials are investigating the long-term effects of mepolizumab and other biologics on asthma control and airway remodeling. Public health surveillance systems, such as those maintained by the Centers for Disease Control and Prevention (CDC), monitor asthma prevalence and exacerbation rates, providing valuable data for informing public health interventions. The CDC’s asthma resources offer comprehensive information for patients, healthcare providers, and researchers.
What comes next involves continued investigation into the mechanisms underlying the protective effect of mepolizumab in patients with small airway dysfunction. Researchers are also exploring biomarkers that could predict treatment response, allowing for more personalized asthma care. Further studies are needed to determine whether early intervention with mepolizumab can prevent airway remodeling and improve long-term asthma outcomes.